source
- Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
- US faces critical shortage of forensic pathologists, delaying justice and public healthThe United States is experiencing a severe deficit of forensic pathologists, with roughly 850 currently practicing-about 400 fewer than experts say are needed to handle more than three million deat…